SNDX

NASDAQ 已收盘

Syndax Pharmaceuticals

9.13 USD
▲+0.57+6.66%
盘后 8.94 -2.08%
2026-11-19
市值
$785.05M
市盈率
—
EPS
-2.37
股息率
—
52 周区间
8.41 – 25.59
成交量
3.31M
Beta
0.45
目标价
32.18
52W 低 8.4152W 高 25.59
价格走势

公司简介

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination...

关联新闻